{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:44:07Z","timestamp":1790408647084,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Limited data are available describing the natural history of patients with HER2-positive and hormone receptor (HR)-positive metastatic breast cancer (MBC). We examined first-line treatment patterns and clinical outcomes in patients with HER2-positive, HR-positive MBC in a real-world setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>registHER is a prospective, observational cohort of 1,023 patients with HER2-positive MBC diagnosed within 6 months of enrollment and followed until death, disenrollment, or June 2009 (median follow-up time: 27 months). Demographics, first-line treatment patterns, and clinical outcomes were examined for 530 HER2-positive, HR-positive patients. Progression-free survival (PFS) and overall survival (OS) times were examined. Multivariate analyses adjusted for baseline demographic and prognostic factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>HER2-positive, HR-positive patients receiving first-line trastuzumab plus hormonal therapy had significantly longer PFS times than patients who received hormonal therapy only (13.8 vs. 4.8 months; adjusted hazard ratio [HR]: 0.37, 95% confidence interval [CI]: 0.22\u20130.60); a nonsignificant reduction in OS time was observed (adjusted HR: 0.55, 95% CI: 0.27\u20131.14). Compared with patients who received first-line trastuzumab plus chemotherapy, patients who received first-line trastuzumab plus chemotherapy and hormonal therapy had longer median PFS times (20.4 months vs. 9.5 months; adjusted HR: 0.53, 95% CI: 0.42\u20130.68); a statistically significant reduction in risk of death was observed (adjusted HR: 0.50, 95% CI: 0.36\u20130.70). Sequential use of chemotherapy and hormonal therapy was associated with improved OS times when compared with concurrent use (adjusted PFS HR: 0.81, 95% CI: 0.54\u20131.21; adjusted OS HR: 0.48, 95% CI: 0.26\u20130.89).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>These real-world data in patients with HER2-positive\/HR-positive MBC provide evidence that, with or without chemotherapy, dual targeting of HRs and HER2 receptors is associated with significantly prolonged PFS and OS times.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2012-0414","type":"journal-article","created":{"date-parts":[[2013,5,8]],"date-time":"2013-05-08T04:21:47Z","timestamp":1367986907000},"page":"501-510","source":"Crossref","is-referenced-by-count":68,"title":["First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER"],"prefix":"10.1093","volume":"18","author":[{"given":"Debu","family":"Tripathy","sequence":"first","affiliation":[{"name":"University of Southern California, Norris Comprehensive Cancer Center, Department of Medicine, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Medical Center, Department of Medicine, Lebanon, New Hampshire, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Brufsky","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Cancer Center, Department of Medicine, Pittsburgh, Pennsylvania, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Mayer","sequence":"additional","affiliation":[{"name":"Patient Advocate, New York, New York, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne Ulcickas","family":"Yood","sequence":"additional","affiliation":[{"name":"EpiSource, LLC, Boston, Massachusetts;"},{"name":"Boston University School of Public Health, Department of Epidemiology, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongin","family":"Yoo","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Quah","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Yardley","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute\/Tennessee Oncology, Department of Internal Medicine, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[{"name":"University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, Department of Medicine, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,5,7]]},"reference":[{"key":"2021122308353433800_B1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"2021122308353433800_B2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122308353433800_B3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122308353433800_B4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3816\/CBC.2005.n.027","article-title":"Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer","volume":"6","author":"Brufsky","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"2021122308353433800_B5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2298\/AOO0604146T","article-title":"Cross-talk between ER and HER2 in breast carcinoma","volume":"14","author":"Todorovic-Rakovic","year":"2006","journal-title":"Arch Oncol"},{"key":"2021122308353433800_B6","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.3816\/CBC.2010.n.014","article-title":"Understanding resistance to endocrine agents: Molecular mechanisms and potential for intervention","volume":"10","author":"Sabnis","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"2021122308353433800_B7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"key":"2021122308353433800_B8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122308353433800_B9","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1158\/1078-0432.CCR-07-4417","article-title":"A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer","volume":"14","author":"Chu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122308353433800_B10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/annonc\/mdn739","article-title":"Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer","volume":"20","author":"Buzdar","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122308353433800_B11","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study","volume":"27","author":"Kaufman","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308353433800_B12","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308353433800_B13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0006-2952(85)90755-5","article-title":"Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro","volume":"34","author":"Goldenberg","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"2021122308353433800_B14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1989.7.6.710","article-title":"Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens","volume":"7","author":"Osborne","year":"1989","journal-title":"J Clin Oncol"},{"key":"2021122308353433800_B15","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1200\/JCO.1985.3.12.1672","article-title":"Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro","volume":"3","author":"Hug","year":"1985","journal-title":"J Clin Oncol"},{"key":"2021122308353433800_B16","first-page":"3998","article-title":"Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells","volume":"43","author":"Sutherland","year":"1983","journal-title":"Cancer Res"},{"key":"2021122308353433800_B17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122308353433800_B18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Amer Statist Assn"},{"key":"2021122308353433800_B19","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.1158\/1078-0432.CCR-10-2051","article-title":"Optimizing chemotherapy-free survival for the ER\/HER2-positive metastatic breast cancer patient","volume":"17","author":"Gl\u00fcck","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"3 suppl","key":"2021122308353433800_B20","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/cncr.23189","article-title":"Combining endocrine agents with chemotherapy: Which patients and what sequence?","volume":"112","author":"Pritchard","year":"2008","journal-title":"Cancer"},{"key":"2021122308353433800_B21","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)61523-3","article-title":"Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"key":"2021122308353433800_B22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cncr.26162","article-title":"Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients","volume":"118","author":"Montemurro","year":"2012","journal-title":"Cancer"},{"key":"2021122308353433800_B23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.44.8027","article-title":"Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006","author":"Rimawi","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2012-0414","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0414","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/5\/501\/41856882\/oncolo_18_5_501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/5\/501\/41856882\/oncolo_18_5_501.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:50:44Z","timestamp":1640307044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/5\/501\/6410231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,1]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5,7]]},"published-print":{"date-parts":[[2013,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0414","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,5,1]]},"published":{"date-parts":[[2013,5,1]]}}}